Mobile Bay Psychedelic Society

06/13/2026

A phase 2a open-label trial published in the Journal of Clinical Psychiatry tested inhaled 5-MeO-DMT (GH001) in ten women with moderate-to-severe postpartum depression.

Using an individualised dosing regimen of up to three escalating doses (6mg, 12mg, 18mg) on a single day, researchers found a mean MADRS reduction of 35.4 points by day 8, corresponding to approximately 96% symptom reduction.

All ten patients achieved full remission, with effects observable just two hours post-dose. Maternal functioning improved by 56%. Suicidal ideation dropped from three patients to zero by discharge. No serious adverse events were reported and all patients were discharged the same day.

Breast milk analysis in lactating patients showed mebufotenin cleared within approximately eight hours. The compound acts as a nonselective serotonin agonist with preferential 5-HT1A affinity and a short plasma half-life, producing a psychoactive window of roughly 20 to 25 minutes per dose.

No psychotherapy was included. Limitations include small sample size, no control arm, and one-week follow-up.

Source: Johnson M et al. Inhaled mebufotenin (GH001) for adult patients with postpartum depression: a phase 2a open-label clinical trial. J Clin Psychiatry. 2026;87(3):25m16284.

06/13/2026

A fascinating preprint about traditional psilocybin use outside the Americas:

“Our study followed an anecdotal report from a Basotho healer, collected by Mamosebetsi Sethathi and published in 2024, who claimed to use the mushroom Psilocybe maluti in a divination ritual. This potentially constituted the first case of traditional psilocybin use outside the Americas, but the initial evidence was weak.”

“Unlike the large ritualized doses characteristic of Mesoamerican psilocybin use, Basotho healers primarily apply small doses of P. maluti alongside other psychoactive plants, most notably the hallucinogenic bulb Boophone disticha. Multiple lines of evidence suggest these practices predate the mid-twentieth-century popularization of psilocybin. These findings expand the known geographic scope of traditional psilocybin use and reveal a mode of psychedelic application distinct from existing ethnographic models.”

Interviewees reported uses in four categories: initiation, healing, recreation, and magical protection.

Full article and an excellent companion piece by Mycostories below:

https://osf.io/preprints/socarxiv/429dw_v1

https://www.mycostories.com/post/psilocybe-maluti-researchers-document-traditional-psilocybin-use-among-basotho-healers-in-southern

Study authors: Eli Stark-Elster, Mamosebetsi Sethathi, Breyten van der Merwe, Sandeep M Nayak, David Bryce Yaden, Manvir Singh

06/13/2026

Texas is leading the charge to turn an African psychedelic into a life-saving drug. But will Iboga’s historic stewards get a cut?

06/07/2026

An 80-year-old Alzheimer's patient hadn't spoken in full sentences for five years. Nineteen hours after taking 5g of psilocybin mushrooms, she talked for four hours, regained continence, dressed herself, and laughed. Then the effects faded.

It didn't surprise me. I've argued that Alzheimer's is a metabolic disease driven by insulin resistance, mitochondrial dysfunction, and neuroinflammation, not simply amyloid buildup. Under that model, neurons don't die immediately. They hibernate.

Two recent studies explain why psilocybin can wake them up. A 2026 study found it triggers active remyelination, rebuilding the brain's signal timing infrastructure. A 2025 Nature study found it extends cellular lifespan, boosts mitochondrial function, and reduces oxidative stress.

Essentially, psilocybin targets the metabolic root causes of the disease.

The improvements faded because the underlying metabolic conditions didn't change. Psilocybin and metabolic therapies like ketogenic diet, fasting, and targeted supplementation may be complementary. One rehabilitates the soil, the other wakes up what's still alive in it.

06/07/2026

ALZHEIMER'S DISEASE AND POTENTIAL TREATMENT WITH MAGIC MUSHROOMS......For any of our military families who have a family member dealing with Alzheimer's disease....Read about this study that gave an elderly patient some temporary improvement in symptoms, just as some improvement has been seen in PTSD symptoms. More research needs to be done...but, it's interesting to see that magic mushrooms may have some future potential to help this disease. "Psilocybin, the psychedelic component of magic mushrooms, has previously been touted as an effective treatment for depression, anxiety, addiction, and PTSD — but now researchers say it has the potential to be used in Alzheimer's intervention as well. It's been previously established that the compounds in psilocybin allow new brain connections to form, and shrooms activate the brain's serotonin receptors, which control things like cognition, mood, and perception. Previous research found that psilocybin could alleviate depression for at least five years after just one dose." READ MORE HERE: https://www.aol.com/articles/alzheimer-patient-gets-back-speech-140553000.html

06/07/2026

Psilocybin proving its healing powers again and again….

BackgroundAdvanced Alzheimer’s disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter lar...

06/07/2026

A patient with advanced Alzheimer’s disease showed remarkable signs of improvement after taking a heroic dose of an experimental hallucinogen.

10/21/2025

The sacred and mythic island of Delos- Inner-lit, with a most sobering psychedelic alchemical clarity.

Humming with palpable antiquity, suspended in time…..

Mobile Bay Psychedelic Society on site in the Ancient Greek island of Delos…..

07/08/2025